(Q44902727)

7 December 2017

title

Galantamine in the treatment of adult autism: a report of three clinical cases (English)

1 reference

7 December 2017

0 references

Marc Hertzman

1

1 reference

7 December 2017

publication date

1 January 2003

1 reference

International Journal of Psychiatry in Medicine

7 December 2017

number of pages

4

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

7 December 2017

volume

33

1 reference

7 December 2017

issue

4

1 reference

7 December 2017

page(s)

395-398

1 reference

Pharmacotherapeutic management of autism

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.2190%2FJE5Q-1NFT-FL40-7PMW

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.2190%2FJE5Q-1NFT-FL40-7PMW

Role of altered brain serotonin mechanisms in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.2190%2FJE5Q-1NFT-FL40-7PMW

Pathophysiology of autism: current opinions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2190%2FJE5Q-1NFT-FL40-7PMW

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2190%2FJE5Q-1NFT-FL40-7PMW

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2190%2FJE5Q-1NFT-FL40-7PMW

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2190%2FJE5Q-1NFT-FL40-7PMW

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2190%2FJE5Q-1NFT-FL40-7PMW

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2190%2FJE5Q-1NFT-FL40-7PMW

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2190%2FJE5Q-1NFT-FL40-7PMW

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2190%2FJE5Q-1NFT-FL40-7PMW

10.2190/JE5Q-1NFT-FL40-7PMW

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference